⚠ Evidence warning: Clinical trials or other evidence do not support the claim that andrographis protects the human liver against acetaminophen, alcohol, fatty liver disease, chronic hepatitis and aflatoxin liver cancer; the evidence is animal and cell work, and no human liver trial was found. This page keeps it as a report of what people, websites or other media say.
Andrographis for Liver Protection
Andrographis has been used as a hepatoprotective remedy in Ayurveda, traditional Chinese medicine, and traditional Thai medicine for at least a thousand years. Its Sanskrit name Bhunimba ("earth neem") explicitly identifies it as the terrestrial counterpart of the bitter bile-supporting neem tree. The Chinese name Chuan Xin Lian (literally "through-heart lotus") points to its use for liver-heat, jaundice, and dampness syndromes. The modern molecular story justifies the traditional use: andrographolide is a cholagogue (stimulates bile production and flow), a Nrf2 activator (induces phase-II detoxification enzymes including glutathione-S-transferase, glutathione peroxidase, NAD(P)H quinone oxidoreductase 1 (NQO1), and heme oxygenase-1), and, in mouse studies, an inducer of the CYP1A1 and CYP1A2 enzymes (it switches them on rather than blocking them). Animal trials document protection against acetaminophen, ethanol, carbon tetrachloride, aflatoxin, and galactosamine hepatotoxicity. This deep-dive walks through the molecular biology, the comparison with the more famous silymarin (milk thistle) model, the clinical applications in fatty liver, hepatitis, and drug-induced liver injury, and the doses described for liver-support uses.
Table of Contents
- Traditional Use as a Hepatoprotective Herb
- Cholagogue Activity (Bile Flow Stimulation)
- Nrf2 / Keap1 / ARE Antioxidant Response
- Phase-II Detoxification Enzyme Induction
- CYP P450 Induction and Carcinogen Bioactivation
- Acetaminophen (Paracetamol) Hepatotoxicity Protection
- Alcohol-Induced Liver Injury
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Aflatoxin and Hepatocarcinogenesis
- Comparison with Silymarin (Milk Thistle)
- Clinical Applications and Dosing
- Cautions and Drug Interactions
- Key Research Papers
- Connections
- Featured Videos
Traditional Use as a Hepatoprotective Herb
Andrographis paniculata appears in the Charaka Samhita (~1st-2nd century CE) and the Sushruta Samhita as a remedy for kamala (jaundice), raktapitta (bleeding disorders associated with liver dysfunction), and chronic fevers with liver involvement. The classical Ayurvedic preparation Kalmegh ghana (a concentrated leaf extract) was prescribed for hepatitis, sluggish digestion, and ascites long before modern hepatology distinguished viral hepatitis from autoimmune hepatitis from drug-induced liver injury. Andrographis remains a constituent of several traditional polyherbal hepatoprotective formulations.
In traditional Chinese medicine, Chuan Xin Lian is classified as a cold, bitter herb that clears heat, dries dampness, and resolves toxin — the classical syndrome pattern that corresponds to modern conditions including acute viral hepatitis, cholangitis, and cholestatic jaundice. It is also used as a primary herb in traditional Chinese medicine formulations for the alarmingly named "damp-heat in the gallbladder" pattern, which translationally corresponds to cholecystitis and cholelithiasis with chronic biliary inflammation.
In traditional Thai medicine, Andrographis (called Fa Thalai Chon) is a Pillar Herb of the National Drug List and is dispensed by the Ministry of Public Health for hepatitis adjunct therapy, along with its better-known upper respiratory tract infection (URTI) applications.
Cholagogue Activity (Bile Flow Stimulation)
A cholagogue is any agent that increases bile flow from the gallbladder into the duodenum (distinct from a choleretic, which increases bile production by hepatocytes — many cholagogues are also choleretics). Improved bile flow matters clinically for several reasons:
- Bile is the principal route of excretion for fat-soluble metabolic waste, bilirubin (from heme breakdown), cholesterol, and many drugs and their conjugated metabolites. Sluggish bile flow allows these to accumulate in the body
- Bile is required for digestion and absorption of dietary fats and fat-soluble vitamins (A, D, E, K). Cholestatic patients develop fat-soluble vitamin deficiencies and steatorrhea
- Bile-acid recycling through the enterohepatic circulation is a major modulator of cholesterol metabolism, bile-acid-receptor (FXR, TGR5) signaling in the gut and liver, and the gut microbiome
- Bile contains bicarbonate that neutralizes gastric acid in the duodenum and creates the alkaline pH required for pancreatic enzyme function
Andrographis is one of a relatively small number of herbs with documented choleretic and cholagogue activity in controlled animal studies. Andrographolide and the related congeners stimulate hepatocyte bile-acid synthesis and increase the rate of bile-salt secretion into the canaliculus. The effect is modest compared with pharmaceutical cholagogues (ursodeoxycholic acid, dehydrocholic acid) but is meaningful in the context of sluggish digestion, gallbladder hypokinesia, and the lingering biliary effects of post-cholecystectomy syndrome.
Andrographis is used for symptoms attributed to poor bile flow — chronic fat malabsorption, pale stools after fatty meals, post-cholecystectomy diarrhea, gallbladder hypomotility on imaging — as part of a broader approach that may also include ox bile, taurine, and smaller amounts of dietary fat.
Nrf2 / Keap1 / ARE Antioxidant Response
The Nrf2 / Keap1 system is the master regulator of cellular antioxidant and phase-II detoxification gene expression. Under baseline conditions, the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is held in the cytoplasm bound to its repressor Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for proteasomal degradation. When the cell experiences oxidative stress, electrophilic challenge, or exposure to specific Nrf2-activating molecules, key reactive cysteine residues on Keap1 are modified, the Keap1-Nrf2 complex dissociates, and Nrf2 translocates to the nucleus.
In the nucleus, Nrf2 heterodimerizes with small Maf proteins and binds the antioxidant response element (ARE) sequence in the promoter regions of over 200 downstream target genes. The downstream targets include:
- Glutathione synthesis enzymes (glutamate-cysteine ligase catalytic and modifier subunits)
- Glutathione-S-transferases (the major phase-II conjugating enzymes for xenobiotic detoxification)
- NAD(P)H quinone oxidoreductase 1 (NQO1, the principal quinone-detoxifying enzyme)
- Heme oxygenase-1 (HO-1, which catabolizes heme and generates the antioxidants biliverdin/bilirubin and the signaling molecule carbon monoxide)
- Catalase, superoxide dismutase, glutathione peroxidase, thioredoxin reductase (the principal cellular antioxidant enzymes)
- Multi-drug resistance proteins (MRP1-4) that pump conjugated xenobiotic metabolites out of the cell into bile
Andrographolide is a documented Nrf2 activator via covalent modification of Keap1 cysteine residues (analogous to the action of sulforaphane from broccoli sprouts, dimethyl fumarate from the multiple sclerosis drug class, and curcumin). Multiple animal models confirm that andrographolide administration upregulates expression of glutathione-S-transferase, NQO1, HO-1, and the glutathione synthesis machinery in liver tissue, with measurable increases in hepatic glutathione concentration after a few weeks of dosing.
The protective effect of Nrf2 induction is broad. It buffers against drug-induced and chemical-induced oxidative damage, accelerates clearance of phase-I-activated reactive intermediates, and reduces the rate at which environmental and metabolic toxins damage hepatic DNA. This is the same mechanism behind the cancer-chemoprevention activity of cruciferous vegetables and is part of the broader case for "induce phase-II, inhibit phase-I" detoxification strategies in chronic illness.
Phase-II Detoxification Enzyme Induction
The conventional hepatic detoxification model divides metabolism into Phase-I (CYP P450-mediated oxidation, reduction, hydrolysis — creates a reactive intermediate from a foreign molecule) and Phase-II (conjugation of the intermediate to glutathione, glucuronide, sulfate, glycine, taurine, methyl — makes it water-soluble for renal or biliary excretion). The reactive Phase-I intermediates are themselves often more toxic than the parent molecule, and the Phase-II enzymes are what neutralize and clear them.
A pattern of relative Phase-I overactivity with Phase-II underactivity is a recurring problem in chronic illness, in genetic detoxification polymorphisms (slow-acetylator NAT2 variants, slow GSTT1/GSTM1 null genotypes), and in the burden of cumulative environmental exposure. The result is accumulation of reactive intermediates that drive chronic oxidative damage and contribute to chemical-induced cancers, autoimmune triggering, and the broad category of multiple chemical sensitivity.
Nrf2 induction is the principal upstream lever for shifting the Phase-I / Phase-II balance toward better conjugation and clearance. Andrographolide is one of the most accessible and well-tolerated Nrf2 activators in the herbal pharmacopeia, alongside sulforaphane (broccoli sprouts), curcumin (turmeric), silymarin (milk thistle), and the carotenoids astaxanthin and beta-carotene.
CYP P450 Induction and Carcinogen Bioactivation
The other half of the detoxification story is Phase-I CYP P450 modulation. The CYP family of approximately 50 hepatic enzymes performs the initial oxidative modification of most foreign molecules — pharmaceuticals, dietary xenobiotics, and many environmental toxins. Three CYP isoforms in particular bioactivate pre-carcinogens into their reactive carcinogenic forms:
- CYP1A1 — converts polycyclic aromatic hydrocarbons (charred meat, cigarette smoke combustion products) into the reactive diol-epoxides that bind DNA and initiate lung and gastric cancer
- CYP1A2 — converts heterocyclic amines (formed in well-done cooked meat) and aromatic amines (bladder carcinogens) into reactive intermediates
- Cytochrome P450 2E1 (CYP2E1) — bioactivates acetaminophen to the hepatotoxic NAPQI intermediate, activates nitrosamines (cured-meat carcinogens), activates carbon tetrachloride and other halogenated solvents
- Cytochrome P450 3A4 (CYP3A4) — metabolizes about half of all clinically used pharmaceuticals; also bioactivates aflatoxin B1 to aflatoxin B1-8,9-epoxide, the proximate carcinogenic species for hepatocellular carcinoma
Laboratory and animal studies show andrographolide switching on (inducing) the bioactivating enzymes, not blocking them. In mouse liver cells, andrographolide raised CYP1A1 and CYP1A2 in a dose-dependent way, and together with standard CYP1A-inducing chemicals (including the smoke-type hydrocarbon benz[a]anthracene and dioxin) it induced CYP1A1 more strongly than either did alone; the authors describe this as the first report of andrographolide's power to induce CYP1A1 (Jaruchotikamol 2007). In mice fed an Andrographis extract (50 or 100 mg/kg a day for 14 days), total liver cytochrome P450 and cytochrome P450 reductase rose, along with the phase-II enzymes glutathione-S-transferase and DT-diaphorase (Singh 2001). What this means for medicines broken down by CYP1A2 (caffeine, theophylline, clozapine) in people has not been tested.
The phase-II side of the picture is what the mouse work supports: Singh and colleagues concluded that the enzyme changes "indicate the chemopreventive potential of Andrographis paniculata against chemotoxicity including carcinogenicity." Long-term andrographolide administration has also been described as reducing polycyclic-aromatic-hydrocarbon-induced gastric tumors and chemically induced mammary tumors in animal models.
Acetaminophen (Paracetamol) Hepatotoxicity Protection
Acetaminophen (US) / paracetamol (UK, much of the world) is among the most-used analgesics globally and the leading cause of acute liver failure in the US and several European countries. The hepatotoxic mechanism is well-mapped: acetaminophen is normally glucuronidated and sulfated for excretion, with a small fraction routed through cytochrome P450 2E1 to the highly reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is normally rapidly neutralized by hepatic glutathione conjugation. When the acetaminophen dose overwhelms the glucuronidation and sulfation pathways (whether by single overdose or by repeated supratherapeutic dosing in chronic-pain patients), more substrate is shunted through cytochrome P450 2E1 to NAPQI, and when hepatic glutathione is depleted, NAPQI binds covalently to hepatocyte proteins causing centrilobular necrosis.
The standard rescue therapy is N-acetylcysteine (NAC, a glutathione precursor) given orally or intravenously within the first hours after overdose. Andrographolide attacks the same problem upstream:
- Inhibits cytochrome P450 2E1 bioactivation of acetaminophen to NAPQI
- Induces glutathione synthesis via Nrf2 activation, maintaining a larger pool to neutralize whatever NAPQI is generated
- Induces glutathione-S-transferase to accelerate the NAPQI-glutathione conjugation
- Reduces nuclear factor kappa B (NF-kB)-driven inflammatory amplification of the initial centrilobular injury
Multiple animal trials in mice and rats document that prophylactic andrographolide administration substantially reduces the liver-enzyme elevation and histologic necrosis from a hepatotoxic acetaminophen dose. Andrographolide is not a substitute for N-acetylcysteine in acute overdose management. Its proposed use as a protective measure for people taking acetaminophen long term above the usual dose for pain (chronic osteoarthritis, cancer pain, post-surgical pain) rests on these animal results.
Alcohol-Induced Liver Injury
Alcoholic liver disease (steatosis, alcoholic hepatitis, fibrosis, cirrhosis) is driven by a combination of acetaldehyde toxicity (the proximate ethanol metabolite produced by alcohol dehydrogenase and cytochrome P450 2E1), oxidative stress from chronic cytochrome P450 2E1 induction, gut-derived endotoxin (lipopolysaccharide) reaching the liver via the portal vein and activating Kupffer cell tumor necrosis factor-alpha and interleukin-6 (IL-6) production, and direct toxic effects on hepatocyte mitochondria.
Andrographolide's hepatoprotective effects in alcohol-induced liver injury are well-documented in animal studies and act through several complementary mechanisms:
- Modest cytochrome P450 2E1 inhibition, reducing the rate of acetaldehyde production
- Glutathione induction, restoring the depleted antioxidant pool that chronic alcohol consumption exhausts
- Nuclear factor kappa B inhibition in Kupffer cells, reducing tumor necrosis factor-alpha amplification of endotoxin-driven inflammation
- Modest gut barrier improvement, reducing the portal endotoxin load that triggers Kupffer activation in the first place
Andrographis has been proposed as an adjunct to alcohol cessation, diet, and conventional management for people in early recovery from alcohol use disorder with elevated liver enzymes, on the strength of these animal studies. It does not make continued drinking safe. The fundamental treatment is alcohol cessation; established alcoholic steatosis takes months to resolve after it.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (now formally renamed metabolic dysfunction-associated steatotic liver disease (MASLD)) affects an estimated 25-30% of adults in developed countries and is now the leading cause of chronic liver disease worldwide. The pathophysiology centers on insulin resistance driving hepatic de novo lipogenesis, mitochondrial dysfunction, oxidative stress, and a chronic low-grade inflammatory state that can progress to non-alcoholic steatohepatitis (NASH, now renamed metabolic dysfunction-associated steatohepatitis, MASH) and ultimately to fibrosis, cirrhosis, and hepatocellular carcinoma.
Animal-model evidence for Andrographis in non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease is encouraging; no human fatty-liver trial of Andrographis was found in PubMed:
- Andrographolide activates AMP-activated protein kinase (AMPK), the master regulator of energy metabolism, with downstream effects including reduced hepatic de novo lipogenesis (suppressed SREBP-1c, ACC, FAS expression), increased fatty acid oxidation, and improved insulin sensitivity
- The same Nrf2 induction discussed above buffers against the oxidative-stress component of non-alcoholic steatohepatitis progression
- Nuclear factor kappa B inhibition reduces the chronic inflammatory state that drives steatosis-to-steatohepatitis progression
- Modest weight reduction and visceral-fat reduction observed in some animal-model studies, although the human evidence is sparse
For non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease management, Andrographis is again described as an adjunct to the foundational interventions (caloric restriction, weight loss of 7-10% of body weight, exercise, low-carbohydrate or Mediterranean dietary pattern, treatment of insulin resistance), not a replacement for them. The regimen described for this use is a 3-6 month course of Andrographis 400-600 mg standardized extract twice daily, alongside the foundational interventions, in people with elevated alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and biopsy-confirmed or imaging-confirmed steatosis; it has not been tested in a human trial.
See our Fatty Liver Disease page for the broader management context.
Aflatoxin and Hepatocarcinogenesis
Aflatoxin B1, produced by Aspergillus flavus mold contamination of stored grain, peanuts, tree nuts, and corn, is one of the most potent natural carcinogens known. Chronic dietary aflatoxin exposure is a major contributor to hepatocellular carcinoma (HCC) incidence in much of sub-Saharan Africa and Southeast Asia, often acting synergistically with chronic hepatitis B virus infection. The molecular mechanism is well-mapped: cytochrome P450 3A4 (and to a lesser extent CYP1A2) oxidizes aflatoxin B1 to the highly reactive aflatoxin-B1-8,9-epoxide, which binds covalently to guanine residues in DNA and produces the characteristic AGG-to-AGT codon-249 mutation in the p53 tumor suppressor gene seen in aflatoxin-driven HCC.
It has been proposed that long-term andrographolide could reduce aflatoxin DNA adduct formation, preneoplastic foci formation in liver, and ultimate HCC incidence; no animal or human study testing this against liver cancer was found in PubMed. The proposed mechanism combined CYP1A2 inhibition (reducing aflatoxin bioactivation), glutathione-S-transferase induction (accelerating conjugation and excretion of whatever epoxide is formed), and AMP-activated protein kinase activation (promoting hepatocyte apoptosis of cells that have sustained DNA damage rather than allowing them to progress to malignant transformation). The first part does not match the laboratory findings: in mouse studies andrographolide induces CYP1A2 rather than inhibiting it (see above). The closest direct study is in farm animals: in pigs fed aflatoxin B1, which suppressed liver genes for detoxification and antioxidant defence, kalmegh (Andrographis) in the feed gave a broad rise in genes of key liver pathways, more than milk thistle did, and the authors conclude such herbs could counteract aflatoxin's effects on liver gene activity (Nalpadan 2026); the study measured gene activity, not cancer.
For people in high-aflatoxin-exposure regions (subsistence farmers, populations dependent on home-stored corn and peanuts), Andrographis has been put forward as a candidate chemopreventive addition to the more important measures of grain-storage modernization, hepatitis B vaccination, and dietary diversification; it has not been tested for this purpose.
Comparison with Silymarin (Milk Thistle)
The most-studied hepatoprotective botanical in Western herbal medicine is silymarin from milk thistle (Silybum marianum), a flavonolignan complex with similar Nrf2-activating and membrane-stabilizing properties to andrographolide. The two herbs are mechanistically complementary rather than redundant:
- Silymarin — stronger membrane-stabilizing effect on hepatocyte plasma membrane (particularly important in amanita mushroom poisoning, the classic indication where intravenous silibinin is approved as primary therapy). Modest Nrf2 activation. Limited CYP inhibition. Modest bile flow stimulation. Extensive evidence base in alcoholic hepatitis, viral hepatitis adjunct, and prevention of chemotherapy-induced liver toxicity.
- Andrographolide — stronger Nrf2 induction and Phase-II enzyme upregulation. Induces (switches on) CYP1A1 and CYP1A2 in mouse studies rather than inhibiting them; described as a modest cytochrome P450 2E1 inhibitor (see the acetaminophen section). Stronger nuclear factor kappa B-mediated anti-inflammatory effect at the Kupffer-cell level. Smaller, mostly animal, evidence base across the same hepatic indications. Additional non-hepatic benefits (upper respiratory tract infection, immune modulation, anti-inflammatory) that silymarin does not provide.
The two are often used together in practice. A combination described for hepatic support in chronic liver disease is silymarin 200-400 mg twice daily plus Andrographis 400 mg standardized extract twice daily, taken with food. The combination is described as well tolerated and mechanistically complementary, and no interactions between the two herbs have been reported.
Clinical Applications and Dosing
Uses and doses described for Andrographis in liver support (none has been tested in a human liver trial; see the Cautions for the human liver-enzyme finding):
- Adjunct to chronic viral hepatitis (B, C) — Andrographis 400-600 mg standardized extract twice daily, alongside standard antiviral therapy. May produce modest reduction in alanine aminotransferase/aspartate aminotransferase and improvement in subjective symptoms. Does not replace antiviral therapy.
- Adjunct to non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease — Andrographis 400-600 mg twice daily, alongside dietary and weight-management foundation. 3-6 month trial.
- Drug-induced liver injury risk reduction — for patients on chronic potentially hepatotoxic medications (high-dose acetaminophen, methotrexate, isoniazid, amiodarone, statins with mildly elevated alanine aminotransferase), Andrographis 400 mg once or twice daily is described as modest hepatic buffering. A Thai study linked recent Andrographis use to small rises in the liver enzyme alanine aminotransferase (see Cautions).
- Alcohol recovery hepatic support — Andrographis 400-600 mg twice daily for the first 3-6 months of recovery, alongside abstinence, diet, and conventional management.
- Cholagogue for sluggish digestion / post-cholecystectomy syndrome — Andrographis 300-400 mg twice daily, often combined with ox bile, taurine, and digestive enzymes.
- General Phase-II detoxification support — Andrographis 300-600 mg daily, often combined with sulforaphane (broccoli sprout extract), curcumin, and silymarin.
All of these uses sit alongside the foundational hepatic-health measures: lower alcohol intake, good macronutrient quality, enough dietary protein for glutathione synthesis (cysteine is the rate-limiting amino acid), a healthy body weight, less exposure to known environmental hepatotoxins (mold-contaminated foods, industrial solvent exposure, unnecessary medications), and treatment of insulin resistance where present.
Cautions and Drug Interactions
- Pregnancy — absolute contraindication. Uterine stimulant. Listed as contraindicated by every major regulatory body. Reiterated on every Andrographis page.
- Cytochrome P450 3A4 substrate drugs — Andrographis has modest cytochrome P450 3A4 inhibitory activity at higher doses. Theoretical risk of increased plasma levels of cytochrome P450 3A4-substrate drugs including immunosuppressants (tacrolimus, cyclosporine), statins (simvastatin, atorvastatin), calcium channel blockers (amlodipine, felodipine), antiarrhythmics (amiodarone, dronedarone), and many others.
- CYP1A2 substrate drugs — in mouse liver cells andrographolide induces CYP1A2 (Jaruchotikamol 2007), so the metabolism of caffeine, theophylline, clozapine, olanzapine and tizanidine could in principle change; this has not been tested in people. Most interactions are described as mild.
- CYP2C19 substrate drugs — in a test-tube study an Andrographis ethanol extract was only a weak inhibitor of CYP2C19 (inhibition constant 67.1 µg/ml), the enzyme that breaks down omeprazole, citalopram and diazepam (Pan 2011).
- Anticoagulants — modest potentiation of warfarin and other anticoagulants. The international normalized ratio (INR) blood test measures this effect.
- Acute fulminant liver failure — Andrographis is not indicated in acute liver failure and is not a substitute for emergency hepatology care, N-acetylcysteine in acetaminophen overdose, or liver transplantation evaluation when indicated.
- Active acute hepatitis with high transaminases — the uses described on this page are for the chronic recovery phase, not the acute inflammatory phase.
- Cholelithiasis (gallstones) with obstruction — Andrographis is a cholagogue and could theoretically increase risk of impacted stone in patients with established symptomatic gallstones. Pain in the upper right abdomen with fever, or yellowing of the skin and eyes, are signs of a blocked bile duct that hospitals treat as urgent.
- Bitter taste and gastric upset — the standard tolerability issues, manageable with capsule form, food, and divided dosing.
- Rises in a liver enzyme in people — in 2021, during Thailand's COVID-19 wave, 168 of 810 patients (20.7%) at a Thai gastroenterology clinic had taken Andrographis in the previous month. Among those with blood tests, users' alanine aminotransferase (ALT) rose more than non-users' since their previous visit (median +2 vs 0 U/L), 44.5% of users vs 32.2% of non-users had a rise of more than 3 U/L, and Andrographis use was independently linked to the rise (adjusted odds ratio 1.62). The authors write that the herb's effect on the liver needs further study (Kaewdech 2022).
- Allergic reactions — Thailand's Health Product Vigilance Center database (2001–2012) held 106 reports of allergic-type reactions in which an Andrographis product was the only suspected cause; 18 were classed as serious (16 needed hospital care). Thirteen involved anaphylactic shock (5), anaphylactic reaction (4) or angioedema (swelling of the face and throat, 4), starting 5 minutes to 1 day after doses of 352 to 1,750 mg (Suwankesawong 2014). Throat or face swelling and trouble breathing are signs hospitals treat as emergencies.
Key Research Papers
- Trivedi NP, Rawal UM (2001). Hepatoprotective and antioxidant property of Andrographis paniculata (Nees) in BHC induced liver damage in mice. Indian Journal of Experimental Biology. — PubMed PMID: 11349524
- Visen PK, Shukla B, Patnaik GK, Dhawan BN (1993). Andrographolide protects rat hepatocytes against paracetamol-induced damage. Journal of Ethnopharmacology. — PubMed PMID: 8133653
- Singh RP, Banerjee S, Rao AR (2001). Modulatory influence of Andrographis paniculata on mouse hepatic and extrahepatic carcinogen metabolizing enzymes and antioxidant status. Phytotherapy Research. — PubMed PMID: 11507728
- Trivedi N, Rawal UM, Patel BP (2007). Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integrative Cancer Therapies. — PubMed PMID: 17761640
- Pan CW, Yang SX, Pan ZZ, et al. (2017). Andrographolide ameliorates d-galactosamine/lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway. Oncotarget. — PubMed PMID: 28465482
- Chua LS (2014). Review on liver inflammation and antiinflammatory activity of Andrographis paniculata for hepatoprotection. Phytotherapy Research. — PubMed PMID: 25043965
- Handa SS, Sharma A (1990). Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride. Indian Journal of Medical Research. — PubMed PMID: 2228074
- Pan Y, Abd-Rashid BA, Ismail Z, et al. (2011). In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). Journal of Ethnopharmacology. — PubMed PMID: 21093571
- Bardi DA, Halabi MF, Hassandarvish P, et al. (2014). Andrographis paniculata leaf extract prevents thioacetamide-induced liver cirrhosis in rats. PLOS ONE. — PubMed
- Nagalekshmi R, Menon A, Chandrasekharan DK, Nair CK (2011). Hepatoprotective activity of Andrographis paniculata and Swertia chirayita. Food and Chemical Toxicology. — PubMed PMID: 21983487
- Jaruchotikamol A, Jarukamjorn K, Sirisangtrakul W, Sakuma T, Kawasaki Y, Nemoto N (2007). Strong synergistic induction of CYP1A1 expression by andrographolide plus typical CYP1A inducers in mouse hepatocytes. Toxicology and Applied Pharmacology. — PubMed PMID: 17825862
- Kaewdech A, Nawalerspanya S, Assawasuwannakit S, Chamroonkul N, Jandee S, Sripongpun P (2022). The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross sectional study. Scientific Reports. — PubMed PMID: 36309577
- Suwankesawong W, Saokaew S, Permsuwan U, Chaiyakunapruk N (2014). Characterization of hypersensitivity reactions reported among Andrographis paniculata users in Thailand using Health Product Vigilance Center (HPVC) database. BMC Complementary and Alternative Medicine. — PubMed PMID: 25539642
- Nalpadan AA, Reyer H, Oster M, et al. (2026). Transcriptional insights into aflatoxin B1 induced hepatotoxicity and comparative effects of medicinal herbs in pigs. BMC Veterinary Research. — PubMed PMID: 41535828
PubMed Topic Searches
Connections
- All Herbs
- Andrographis Overview
- Andrographis Benefits Hub
- Andrographis for Cold & Flu
- Andrographis Immune Modulation
- Andrographis Anti-Inflammatory
- Milk Thistle (Silymarin)
- Turmeric (Curcumin)
- Dandelion
- N-Acetylcysteine
- Taurine (Bile Conjugation)
- Glutathione
- Fatty Liver Disease (Non-Alcoholic Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease)
- Hepatitis
- Mold and Mycotoxins (Aflatoxin)
- Liver Function Tests (Alanine Aminotransferase/Aspartate Aminotransferase/Gamma-Glutamyl Transferase)
- History